|Fastest Growing Market:||Asia-Pacific|
|Largest Market:||North America|
Need a report that reflects how COVID-19 has impacted this market and its growth?
The carboprost tromethamine market is projected to register a CAGR of 3.9% during the forecast period (2022 – 2027).
With the increase in COVID-19, there has been an increase in other complications that arise along with the infection. According to the American College of Obstetricians and Gynecologists' COVID-19 FAQs for Obstetrician - Gynecologists, Obstetrics updated in July 2020, carboprost tromethamine is contraindicated in pregnant women with asthma or other respiratory problems because the drug is associated with the occurrence of bronchospasm. The article mentions that although there are no specific data regarding the infection of COVID-19 with the use of carboprost tromethamine, the indications of COVID-19, especially viral pneumonia, can be a concern. As COVID-19 increases the risk of thrombosis due to the hypercoagulable state of pregnancy, the use of carboprost tromethamine should be carefully consulted before administration. An article presented in the journal Anesthesia and Analgesia in March 2020 reported a case of bronchospasm during the treatment of postpartum hemorrhage with carboprost tromethamine. The patient tested positive for COVID-19, which may have affected the treatment of postpartum hemorrhage. With the declining number of COVID cases, the adverse effects of the virus on the treatment of postpartum hemorrhage are expected to decrease, thereby fuelling the market growth over the forecast period.
Postpartum hemorrhage is the leading cause of maternal death worldwide. According to the 2020 article on Maternal Morbidity and Mortality from the National Institute of Health's Eunice Kennedy Shriver National Institute of Child Health and Human Development department of the United States Department of Health and Human Services, hemorrhage (also known as bleeding) is one of the leading causes of maternal mortality and morbidity. The number of postpartum cases worldwide is also increasing. According to an article published by the Commonwealth Fund in December 2020, severe postpartum hemorrhage accounts for about 11.1% of maternal mortality in the United States. Furthermore, an article published on Abortion by the World Health Organization in November 2021 confirmed the increasing rate of atonic postpartum hemorrhage in Saudi Arabia. It also reported that around 73.0 million induced abortions would take place worldwide annually. World Health Organization has included comprehensive abortion care in the list of essential health services for 2020. The increasing cases of postpartum hemorrhage and the increase in the number of abortions require appropriate drugs for the treatment and prevention of maternal mortality. Therefore, such an increase is expected to fuel the growth of the carboprost tromethamine market over the forecast period.
Scope of the Report
As per the scope of this report, carboprost tromethamine is a prostaglandin indicated for the treatment of bleeding due to postpartum hemorrhage and for producing abortion by causing uterine contractions. The carboprost tromethamine market is segmented by Application (Postpartum Hemorrhage Treatment and Pregnancy Abortion), Distribution Channel (Hospital Pharmacies, Retail pharmacies, and Online Pharmacies), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The Market report also covers the estimated market sizes and trends of 17 countries across major regions globally. The report offers values in (USD million) for the above segments.
|Postpartum Hemorrhage Treatment|
|By Distribution Channel|
Key Market Trends
The Postpartum Hemorrhage Treatment Segment is Expected to Hold a Major Market Share in the Carboprost Tromethamine Market
Postpartum hemorrhage is one of the major causes of maternal morbidity and mortality. According to World Health Organisation’s data on Maternal, Newborn, Child, and Adolescent Health and Ageing, in 2021, India had the largest number of births in the world with approximately 24,016,020 thousand, followed by China with 15,918,889 thousand. The high birth rate also results in an increase in the number of cases of postpartum hemorrhage. An article published by the BMC Journal of Reproductive Health in March 2022 estimates that postpartum mortality is one of the leading causes of maternal mortality in developing countries, accounting for approximately 25.0–43.0% of total maternal deaths. The article also indicated that the extent of postpartum hemorrhage among mothers after childbirth in Ethiopia is moderately high. Such an increase in cases of postpartum hemorrhage is expected to surge the demand for the treatment, thereby propelling the sale of carboprost tromethamine injections.
An article published in the Tropical Journal of Pharmaceutical Research in May 2020 studied the effects of carboprost tromethamine in the treatment of cesarean-associated postpartum hemorrhage and concluded that carboprost tromethamine prevents postpartum hemorrhage after cesarean section. The study also indicated that it effectively reduces bleeding and promotes uterine involution, with no apparent adverse reactions. Recent research has also focused on the combination therapy of carboprost tromethamine with other drugs for their effect on postpartum hemorrhage. An article published in the journal; Medicine in July 2021 revealed the effectiveness of carboprost tromethamine in combination with Leonurus Japonicus injection for the prevention of postpartum hemorrhage in high-risk pregnant women. The study indicated that the prophylactic use of Leonurus Japonicus Injection in combination with carboprost tromethamine might have a good effect on the prevention of postpartum hemorrhage after childbirth. Research into the use of carboprost tromethamine is of great importance, and the scope of research work being carried out on further therapy is considerable.
These factors are expected to have a significant impact on the growth of the carboprost tromethamine market in the upcoming period.
To understand key trends, Download Sample Report
North America is Expected to Dominate the Carboprost Tromethamine Market
The carboprost tromethamine market is expected to witness significant growth in the North American region during the forecast period. According to the World Health Organization, the number of births in the United States for the year 2021 is 3,985,712 thousand. A high number of births is associated with an increasing number of cases of postpartum hemorrhage. The number of live births is expected to reach approximately 4,124,888 thousand by 2050. The National Institute for Child Health Quality revealed in April 2022 that approximately 3.0% of births in the United States reported cases of postpartum hemorrhage. These cases represented more than 100,000 births per year. The above source also showed that hospitals might be able to prevent up to 70.0% of bleeding-related obstetric deaths. The right treatment strategies could help reduce maternal mortality in the United States. Carboprost Tromethamine is intended to suppress the effects of postpartum bleeding in pregnant women. Thus, the carboprost tromethamine market is expected to grow in the North American region during the forecast period.
Key product launches, high concentration of market players or manufacturer presence and acquisitions and partnerships between major players, and high pregnancy rates in the United States are some of the factors driving the growth of the carboprost tromethamine market in the country. For example, according to the United Health Foundation America's Health Rankings for 2021, the United States had approximately 30.6% of unintended pregnancies during the year. In addition, increased awareness and advantages of the treatment may increase the use of carboprost tromethamine in the United States. For example, according to an article published in the IOSR Journal of Dental and Medical Sciences in June 2020, carboprost tromethamine was reported to be 84.0-96.0% effective in treating persistent bleeding due to uterine atony and may avoid the need for surgery. Therefore, such a positive result may increase the demand for carboprost Tromethamine in the United States. In addition, the increase in research and development by companies in the clinical stage of new treatments for postpartum hemorrhage is anticipated to fuel the growth of the carboprost tromethamine market in the country. Therefore, due to the above-mentioned factors, the country is expected to experience a high growth rate during the forecast period. Hence, due to the above-mentioned factors, a high growth rate is anticipated in the country over the forecast period.
To understand geography trends, Download Sample Report
The carboprost tromethamine market is fragmented and competitive and consists of several major players. In terms of market share, a few of the major players are currently dominating the market. The competitive landscape includes an analysis of a few international as well as local companies which hold the market shares and are well known, including Pfizer, ChemScene, Universal Biologicals, Woodward Pharma, Amneal Pharmaceuticals LLP, Dr. Reddy's Laboratories Ltd., Merck KGaA, Bio-Techne, and SimSon Pharma Limited, among others.
- In February 2022, Amneal Pharmaceuticals LLP announced that the Food and Drug Administration (FDA) approved Carboprost Tromethamine Injection. It is indicated for aborting pregnancy between the 13th and 20th weeks of gestation as calculated from the first day of the last normal menstrual period and the conditions related to second-trimester abortion.
- In March 2021, Sunny Pharmatech Inc. announced the approval of ANDA (Abbreviated New Drug Application) of Carboprost Tromethamine Injection by the Food and Drug Administration (FDA). Carboprost Tromethamine Injection is indicated for aborting the pregnancy.
Table of Contents
1.1 Study Assumptions and Market Defination
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Postpartum Hemorrhage
4.2.2 Increasing Demand for Contraceptive Pills
4.3 Market Restraints
4.3.1 Side Effects Associated With the Administration of Carboprost Tromethamine
4.3.2 Lack of Awareness Among Rural Population
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Application
5.1.1 Postpartum Hemorrhage Treatment
5.1.2 Pregnancy Abortion
5.2 By Distribution Channel
5.2.1 Hospital Pharmacies
5.2.2 Retail Pharmacies
5.2.3 Online Pharmacies
5.3.1 North America
188.8.131.52 United States
184.108.40.206 United Kingdom
220.127.116.11 Rest of Europe
18.104.22.168 South Korea
22.214.171.124 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
126.96.36.199 South Africa
188.8.131.52 Rest of Middle-East and Africa
5.3.5 South America
184.108.40.206 Rest of South America
6. COMPETITIVE LANDSCAPE
*List Not Exhaustive
6.1 Company Profiles
6.1.1 Amneal Pharmaceuticals LLP
6.1.3 Dr. Reddy's Laboratories Ltd.
6.1.4 Merck KGaA
6.1.6 Universal Biologicals
6.1.7 Woodward Pharma
6.1.8 BioSpectra, Inc.
6.1.9 ANGUS Chemical Company
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
You can also purchase parts of this report. Do you want to check out a section wise price list?
Frequently Asked Questions
What is the study period of this market?
The Global Carboprost Tromethamine Market market is studied from 2019 - 2027.
What is the growth rate of Global Carboprost Tromethamine Market?
The Global Carboprost Tromethamine Market is growing at a CAGR of 3.9% over the next 5 years.
Which region has highest growth rate in Global Carboprost Tromethamine Market?
Asia-Pacific is growing at the highest CAGR over 2021- 2026.
Which region has largest share in Global Carboprost Tromethamine Market?
North America holds highest share in 2021.
Who are the key players in Global Carboprost Tromethamine Market?
Merck KGaA, Pfizer, Universal Biologicals, Woodward Pharma, ChemScene are the major companies operating in Global Carboprost Tromethamine Market.